Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$5.72 -3.9%	$5.85	$3.79 ▼ $14.60	$312.93M	-0.88	1.04 million shs	293,749 shs
FDMT 4D Molecular Therapeutics	$6.72 -5.3%	$4.93	$2.23 ▼ $17.41	$311.72M	2.83	877,302 shs	505,336 shs
INBX Inhibrx Biosciences	$24.98 -0.1%	$20.30	$10.81 ▼ $25.61	$365.69M	0.24	105,993 shs	46,886 shs
ORMP Oramed Pharmaceuticals	$2.17 +1.2%	$2.14	$1.82 ▼ $3.09	$88.77M	1.6	139,977 shs	170,215 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	0.00%	-2.30%	-15.24%	+9.58%	+4.75%
FDMT 4D Molecular Therapeutics	0.00%	-2.34%	+55.14%	+103.15%	-52.61%
INBX Inhibrx Biosciences	0.00%	+7.16%	+8.32%	+94.40%	+87.41%
ORMP Oramed Pharmaceuticals	0.00%	+2.88%	-0.93%	+0.94%	-13.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CADL Candel Therapeutics	2.3442 of 5 stars	3.6	2.0	0.0	1.7	1.7	0.6
FDMT 4D Molecular Therapeutics	2.0066 of 5 stars	3.3	2.0	0.0	1.6	1.7	0.6
INBX Inhibrx Biosciences	1.3783 of 5 stars	0.0	3.0	4.6	2.0	1.7	0.0
ORMP Oramed Pharmaceuticals	0.9652 of 5 stars	0.0	3.0	0.0	3.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	3.20	Buy	$22.00	284.95% Upside
FDMT 4D Molecular Therapeutics	2.64	Moderate Buy	$30.40	352.72% Upside
INBX Inhibrx Biosciences	2.00	Hold	N/A	N/A
ORMP Oramed Pharmaceuticals	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest ORMP, FDMT, INBX, and CADL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	INBX Inhibrx Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
8/14/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
8/12/2025	FDMT 4D Molecular Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
8/12/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
8/1/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/29/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
7/12/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
7/9/2025	CADL Candel Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/3/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/30/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$23.00
6/27/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	$120K	2,614.61	N/A	N/A	$1.41 per share	4.05
FDMT 4D Molecular Therapeutics	$40K	7,839.76	N/A	N/A	$11.05 per share	0.61
INBX Inhibrx Biosciences	$200K	1,808.84	$118.97 per share	0.21	$9.23 per share	2.71
ORMP Oramed Pharmaceuticals	$2M	44.39	N/A	N/A	$3.61 per share	0.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$55.18M	-$0.69	N/A	N/A	N/A	N/A	-41.00%	-26.81%	11/13/2025 (Estimated)
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.53	N/A	N/A	N/A	-594,375.81%	-40.15%	-36.43%	11/12/2025 (Estimated)
INBX Inhibrx Biosciences	$1.69B	-$10.58	N/A	N/A	N/A	N/A	-137.83%	-76.31%	11/13/2025 (Estimated)
ORMP Oramed Pharmaceuticals	-$19.06M	-$0.35	N/A	N/A	N/A	N/A	-19.37%	-18.28%	11/6/2025 (Estimated)

Latest ORMP, FDMT, INBX, and CADL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CADL Candel Therapeutics	-$0.17	-$0.09	+$0.08	-$0.09	N/A	N/A
8/14/2025	Q2 2025	ORMP Oramed Pharmaceuticals	-$0.04	-$0.05	-$0.01	$0.31	N/A	N/A
8/13/2025	Q2 2025	INBX Inhibrx Biosciences	-$2.92	-$1.85	+$1.07	-$1.85	N/A	$1.30 million
8/11/2025	Q2 2025	FDMT 4D Molecular Therapeutics	-$0.88	-$0.98	-$0.10	-$0.98	$0.52 million	$0.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	0.01	7.04	7.04
FDMT 4D Molecular Therapeutics	N/A	8.75	8.75
INBX Inhibrx Biosciences	1.45	4.98	4.98
ORMP Oramed Pharmaceuticals	N/A	26.82	26.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
FDMT 4D Molecular Therapeutics	99.27%
INBX Inhibrx Biosciences	82.46%
ORMP Oramed Pharmaceuticals	12.73%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	16.60%
FDMT 4D Molecular Therapeutics	9.60%
INBX Inhibrx Biosciences	N/A
ORMP Oramed Pharmaceuticals	17.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	60	54.90 million	45.78 million	Optionable
FDMT 4D Molecular Therapeutics	120	46.70 million	42.22 million	Optionable
INBX Inhibrx Biosciences	166	14.48 million	N/A	Optionable
ORMP Oramed Pharmaceuticals	10	41.00 million	33.71 million	Optionable

ORMP, FDMT, INBX, and CADL Headlines

Recent News About These Companies

Oramed Pharm Approves Stock Incentive Plan Amendment

August 21, 2025 | tipranks.com

Oramed Pharmaceuticals (NASDAQ:ORMP) Posts Earnings Results, Misses Expectations By $0.01 EPS

August 18, 2025 | marketbeat.com

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Passes Below Two Hundred Day Moving Average - Time to Sell?

August 15, 2025 | marketbeat.com

Oramed Pharmaceuticals (ORMP) to Release Earnings on Wednesday

August 7, 2025 | marketbeat.com

Zacks Small Cap Has Negative Outlook for ORMP Q2 Earnings

August 1, 2025 | marketbeat.com

With Substantial Liquidity, ORMP Has Generated Gains & Income From Investment Portfolio

July 29, 2025 | msn.com

BML Capital Management LLC Raises Position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

July 26, 2025 | marketbeat.com

ORMP - Oramed Pharmaceuticals Inc Trailing Returns - Morningstar

July 2, 2025 | morningstar.comM

Oramed Pharmaceuticals Inc. (ORMP) - Yahoo Finance

July 2, 2025 | ca.finance.yahoo.com

ORMP - Oramed Pharmaceuticals Inc Executives - Morningstar

June 27, 2025 | morningstar.comM

We're Not Very Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Rate

June 27, 2025 | finance.yahoo.com

Oramed Pharm Extends Stock Buyback Program

May 21, 2025 | tipranks.com

The past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable

May 17, 2025 | finance.yahoo.com

Oramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

April 28, 2025 | finanznachrichten.de

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

April 28, 2025 | globenewswire.com

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

April 28, 2025 | prnewswire.com

ORMP: Upcoming Expected Milestones Include OraTech Spin-Off & IPO, Launch of Phase 3 Trial

April 3, 2025 | finance.yahoo.com

Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential

March 15, 2025 | finance.yahoo.com

Oramed Pharmaceuticals Issues Letter to Shareholders

March 4, 2025 | prnewswire.com

OraMed Enters Global Licensing Deal for Lidocaine Product

March 1, 2025 | investing.com

Congressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals Stock

February 27, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP, FDMT, INBX, and CADL Company Descriptions

Candel Therapeutics NASDAQ:CADL

$5.72 -0.24 (-3.95%)

As of 03:47 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

4D Molecular Therapeutics NASDAQ:FDMT

$6.72 -0.38 (-5.29%)

As of 03:47 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Inhibrx Biosciences NASDAQ:INBX

$24.98 -0.02 (-0.06%)

As of 03:47 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Oramed Pharmaceuticals NASDAQ:ORMP

$2.16 +0.03 (+1.17%)

As of 03:41 PM Eastern

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time